A Dutch court has rejected a shareholder demand to investigate Philips over alleged misleading disclosures and management failures surrounding the company’s recall of millions of sleep apnea devices, giving the health technology group a legal reprieve as investigations into the recall continue in other countries.
The Enterprise Chamber of the Amsterdam Court of Appeal ruled on Saturday that it found no indication Philips had known about the problems with the devices long before issuing a warning. The court also found no reason to conclude that executives should have intervened earlier at Respironics, the subsidiary responsible for manufacturing the affected machines.
The decision followed a demand by a large group of shareholders for a formal inquiry into Philips’ handling of the problems. The investors alleged that company executives had reacted too slowly to the issues that prompted the recall and failed to provide investors with adequate information about the risks.
Register for the next Tekedia Mini-MBA.
Register for Tekedia AI in Business Masterclass.
Join Tekedia Capital Syndicate and co-invest in great global startups.
Philips denied the allegations and said it welcomed the ruling.
The court’s decision addresses the shareholders’ request for an inquiry into the company’s conduct. It does not, however, erase the financial and reputational consequences of the recall or end the separate investigations and legal proceedings associated with the affected devices.
Philips recalled around 15 million sleep apnea devices in 2021 after discovering that foam used inside the machines could release harmful substances and potentially pose health risks to users. The recall triggered widespread scrutiny of the company’s product safety controls, disclosures and oversight of its Respironics business.
The financial consequences were severe. Philips’ shares lost about two-thirds of their value as investors reassessed the company’s exposure to litigation, regulatory action and the costs of addressing the defective devices.
The dispute subsequently extended beyond the immediate safety concerns to questions about when Philips became aware of the problems, how quickly management responded and whether investors received sufficient information to evaluate the company’s risks. Shareholders seeking a court inquiry argued that executives had responded too late to the issues and failed to communicate adequately with the market. Their demand sought closer scrutiny of management decisions surrounding the recall and the company’s handling of the underlying problems.
The Enterprise Chamber’s ruling rejected the basis for that inquiry, finding no indication that Philips had known about the problems substantially earlier than its warning and no reason to assume that management should have intervened sooner at Respironics.
The decision provides an important distinction between the seriousness of a product recall and whether the available evidence justifies a formal investigation into alleged management failures. The recall affected millions of devices and caused substantial losses for investors, but those consequences alone did not establish the allegations advanced by the shareholders.
The ruling now removes one avenue of legal scrutiny over Philip’s conduct in the Netherlands. The company nevertheless remains exposed to the broader consequences of the recall, including proceedings in other jurisdictions and the financial settlements already reached with affected users.
US Settlement and French Investigation Continue
The recall has prompted investigations in several countries, demonstrating that the legal fallout extends beyond the shareholder dispute in the Netherlands.
In France, prosecutors are continuing to investigate allegations involving aggravated fraud and failure to report safety risks. Those proceedings remain separate from the Dutch court’s assessment of whether there were grounds for a formal inquiry into Philips’ management and disclosures.
That matters because different proceedings can examine different conduct, legal obligations and evidence. The Dutch ruling does not, by itself, determine the outcome of the French investigation or resolve every question concerning the devices’ safety and the company’s response.
Philips has also faced substantial financial liabilities in the United States. In 2024, the company agreed to pay $1.1 billion to settle all personal injury claims related to the devices that had been filed in the country. That settlement represented a major financial consequence of the recall, which developed into a prolonged legal and operational challenge for the company. The need to address personal injury claims, alongside regulatory scrutiny and the costs associated with the affected products, weighed on investor confidence after the recall was announced.
The Dutch decision does not reverse the US settlement or eliminate the costs Philips has already incurred. Instead, it narrows one particular dispute: shareholders’ establishment of sufficient grounds for a formal judicial investigation into alleged failures by the company’s leadership.
Management Accountability Remains a Major Issue
The shareholder challenge, however, reveals the broader governance questions that can follow a major product safety failure. Investors often seek to determine whether problems arose from manufacturing defects alone or whether earlier warnings, internal oversight and corporate disclosures could have reduced the eventual damage.
In Philips’ case, the shareholders argued that management should have acted sooner and communicated more effectively. The court, however, said it found no indication that the company had known about the problems long before it issued a warning, and it did not consider an earlier intervention by executives at Respironics to be warranted on the basis presented.
That finding is significant for the specific inquiry sought by investors, but the broader consequences of the recall remain. The case has exposed Philips to legal costs, financial settlements, and sustained scrutiny of the processes used to identify and communicate product safety risks.
However, the incident has exposed investors to financial downturn. A recall can trigger steep share-price losses and years of litigation without necessarily establishing that executives deliberately withheld information or knowingly failed to act.
Philips welcomed the Dutch court’s decision. But the ruling marks a setback for shareholders seeking a formal investigation in the Netherlands, rather than a comprehensive resolution of the recall’s wider fallout.